SLE thrombosis
high risk
monitoring SLE patients
Accurate assessment of thrombosis risk
highest risk
life-threatening complication of SLE
GBS forecasts
high healthcare costs
thrombosis-related complications
systemic lupus erythematosus Patients
introduction of ThromboSLE
ThromboSLE sales
accurate identification of patients
high sensitivity
SMEi phase
total median costs
rehabilitation cost
direct cost
target market Western Europe
Thrombotic events
anticoagulant prophylaxis
market readiness
diagnostic product
innovative test
business strategy
thrombotic event management
strong business opportunity
cellular components
respect
functional analysis of blood plasma
Dutch SME Good Biomarker Sciences
benefit ratio
times lower
interventions
current testing methods
disease-specific mechanism
company growth
substantial impact
cumulated profits
group
unique expertise
final verification
mortality
feasibility study
hospitals
main causes of death
economic viability
commercial exploitation
innovation project
morbidity
need
specificity